	US 12,257,232 B2
	Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias
Laurence Legeai-Mallet, Paris (FR); Antonio Segura Carretero, Granada (ES); and Maria De La Luz Cadiz Gurrea, Granada (ES)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); FONDATION IMAGINE, Paris (FR); ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), Paris (FR); and UNIVERSIDAD DE GRANADA, Granada (ES)
Filed by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, Paris (FR); UNIVERSITE PARIS CITE, Paris (FR); FONDATION IMAGINE, Paris (FR); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), Paris (FR); and UNIVERSIDAD DE GRANADA, Granada (ES)
Filed on Sep. 8, 2023, as Appl. No. 18/463,707.
Application 18/463,707 is a continuation of application No. 16/964,781, granted, now 11,951,090, previously published as PCT/EP2019/051622, filed on Jan. 23, 2019.
Claims priority of application No. 18305053 (EP), filed on Jan. 24, 2018.
Prior Publication US 2023/0414561 A1, Dec. 28, 2023
Int. Cl. A61K 31/353 (2006.01); A61P 19/00 (2006.01)

CPC A61K 31/353 (2013.01) [A61P 19/00 (2018.01)]

3 Claims

1. A method of treating a FGFR3-related chondrodysplasia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a substantially pure (−)-epicatechin in a pharmaceutical composition that does not comprise flavonols, sweroside, hexenyl 5 xylopyranosyl glucopyranoside, procyanidin, catechin, cinchonain, or quercitin.